SparingVision, a spin-off from the Paris Vision Institute, is a genomic medicines company, translating pioneering science into vision-saving treatments.
SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies.
SparingVision was founded in 2016 by Thierry Léveillard. The company is headquartered in Paris, France and Philadelphia, Pennsylvania.
SparingVision, by leveraging its unparalleled understanding of retinal diseases, has built the world's most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for inherited retinal diseases (IRDs).
SparingVision's lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide.
SparingVision's SPVN06 and SPVN20, go beyond single gene correction therapies to deliver new mutation-agnostic treatments for retinitis pigmentosa (RP), a group of IRDs which are a leading cause of blindness globally.
SparingVision is backed by 4BIO Capital, Bpifrance, UPMC Enterprises, RD Fund, Jeito Capital, Ysios Capital, Voir & Entendre (FVE), Foundation Fighting Blindness, Advent France Biotechnology, and others. The company raised €75M in Series B round on Sep 15, 2022. This brings SparingVision's total funding to €135M to date.